96
views
0
recommends
+1 Recommend
0 collections
    10
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Altered PLP1 splicing causes hypomyelination of early myelinating structures

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          The objective of this study was to investigate the genetic etiology of the X-linked disorder “Hypomyelination of Early Myelinating Structures” (HEMS).

          Methods

          We included 16 patients from 10 families diagnosed with HEMS by brain MRI criteria. Exome sequencing was used to search for causal mutations. In silico analysis of effects of the mutations on splicing and RNA folding was performed. In vitro gene splicing was examined in RNA from patients’ fibroblasts and an immortalized immature oligodendrocyte cell line after transfection with mutant minigene splicing constructs.

          Results

          All patients had unusual hemizygous mutations of PLP1 located in exon 3B (one deletion, one missense and two silent), which is spliced out in isoform DM20, or in intron 3 (five mutations). The deletion led to truncation of PLP1, but not DM20. Four mutations were predicted to affect PLP1/ DM20 alternative splicing by creating exonic splicing silencer motifs or new splice donor sites or by affecting the local RNA structure of the PLP1 splice donor site. Four deep intronic mutations were predicted to destabilize a long-distance interaction structure in the secondary PLP1 RNA fragment involved in regulating PLP1/ DM20 alternative splicing. Splicing studies in fibroblasts and transfected cells confirmed a decreased PLP1/DM20 ratio.

          Interpretation

          Brain structures that normally myelinate early are poorly myelinated in HEMS, while they are the best myelinated structures in Pelizaeus–Merzbacher disease, also caused by PLP1 alterations. Our data extend the phenotypic spectrum of PLP1-related disorders indicating that normal PLP1/ DM20 alternative splicing is essential for early myelination and support the need to include intron 3 in diagnostic sequencing.

          Related collections

          Most cited references46

          • Record: found
          • Abstract: found
          • Article: not found

          Role of RNA structure in regulating pre-mRNA splicing.

          Pre-mRNA splicing involves removing non-coding introns from RNA transcripts. It is carried out by the spliceosome, along with other auxiliary factors. In general, research in splicing has focused on the sequences within the pre-mRNA, without considering the structures that these sequences might form. We propose that the role of RNA structure deserves more consideration when thinking about splicing mechanisms. RNA structures can inhibit or aid binding of spliceosomal components to the pre-mRNA, or can increase splicing efficiency by bringing important sequences into close proximity. Recent reports have identified proteins and small molecules that can regulate splicing by modulating RNA structures, thereby expanding our knowledge of the mechanisms used to regulate splicing. Copyright 2009 Elsevier Ltd. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Magnetic resonance imaging pattern recognition in hypomyelinating disorders.

            Hypomyelination is observed in the context of a growing number of genetic disorders that share clinical characteristics. The aim of this study was to determine the possible role of magnetic resonance imaging pattern recognition in distinguishing different hypomyelinating disorders, which would facilitate the diagnostic process. Only patients with hypomyelination of known cause were included in this retrospective study. A total of 112 patients with Pelizaeus-Merzbacher disease, hypomyelination with congenital cataract, hypomyelination with hypogonadotropic hypogonadism and hypodontia, Pelizaeus-Merzbacher-like disease, infantile GM1 and GM2 gangliosidosis, Salla disease and fucosidosis were included. The brain scans were rated using a standard scoring list; the raters were blinded to the diagnoses. Grouping of the patients was based on cluster analysis. Ten clusters of patients with similar magnetic resonance imaging abnormalities were identified. The most important discriminating items were early cerebellar atrophy, homogeneity of the white matter signal on T(2)-weighted images, abnormal signal intensity of the basal ganglia, signal abnormalities in the pons and additional T(2) lesions in the deep white matter. Eight clusters each represented mainly a single disorder (i.e. Pelizaeus-Merzbacher disease, hypomyelination with congenital cataract, hypomyelination with hypogonadotropic hypogonadism and hypodontia, infantile GM1 and GM2 gangliosidosis, Pelizaeus-Merzbacher-like disease and fucosidosis); only two clusters contained multiple diseases. Pelizaeus-Merzbacher-like disease was divided between two clusters and Salla disease did not cluster at all. This study shows that it is possible to separate patients with hypomyelination disorders of known cause in clusters based on magnetic resonance imaging abnormalities alone. In most cases of Pelizaeus-Merzbacher disease, hypomyelination with congenital cataract, hypomyelination with hypogonadotropic hypogonadism and hypodontia, Pelizaeus-Merzbacher-like disease, infantile GM1 and GM2 gangliosidosis and fucosidosis, the imaging pattern gives clues for the diagnosis.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Mutations in DARS cause hypomyelination with brain stem and spinal cord involvement and leg spasticity.

              Inherited white-matter disorders are a broad class of diseases for which treatment and classification are both challenging. Indeed, nearly half of the children presenting with a leukoencephalopathy remain without a specific diagnosis. Here, we report on the application of high-throughput genome and exome sequencing to a cohort of ten individuals with a leukoencephalopathy of unknown etiology and clinically characterized by hypomyelination with brain stem and spinal cord involvement and leg spasticity (HBSL), as well as the identification of compound-heterozygous and homozygous mutations in cytoplasmic aspartyl-tRNA synthetase (DARS). These mutations cause nonsynonymous changes to seven highly conserved amino acids, five of which are unchanged between yeast and man, in the DARS C-terminal lobe adjacent to, or within, the active-site pocket. Intriguingly, HBSL bears a striking resemblance to leukoencephalopathy with brain stem and spinal cord involvement and elevated lactate (LBSL), which is caused by mutations in the mitochondria-specific DARS2, suggesting that these two diseases might share a common underlying molecular pathology. These findings add to the growing body of evidence that mutations in tRNA synthetases can cause a broad range of neurologic disorders. Copyright © 2013 The American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.
                Bookmark

                Author and article information

                Journal
                Ann Clin Transl Neurol
                Ann Clin Transl Neurol
                acn3
                Annals of Clinical and Translational Neurology
                John Wiley & Sons, Ltd (Chichester, UK )
                2328-9503
                2328-9503
                June 2015
                01 May 2015
                : 2
                : 6
                : 648-661
                Affiliations
                [1 ]Department of Child Neurology, VU University Medical Center Amsterdam, The Netherlands
                [2 ]Neuroscience Campus Amsterdam, VU University Amsterdam, The Netherlands
                [3 ]Nemours Biomedical Research, Alfred I. duPont Hospital for Children Wilmington, Delaware
                [4 ]Department of Clinical Genetics, VU University Medical Center Amsterdam, The Netherlands
                [5 ]Unit for Neuromuscular and Neurodegenerative Diseases, Laboratory of Molecular Medicine, Bambino Gesu’ Children’s Research Hospital, IRCCS Rome, Italy
                [6 ]Department of Pediatrics, McMaster Children’s Hospital Hamilton, Ontario, Canada
                [7 ]Child Neuropsychiatry Unit, Department of Brain and Behavioral Sciences, University of Pavia Pavia, Italy
                [8 ]Department of Medicine and Surgery, University of Salerno Salerno, Italy
                [9 ]CSS-Mendel Institute, IRCCS Casa Sollievo della Sofferenza San Giovanni Rotondo, Italy
                [10 ]Division of Pediatric Neurology, Departments of Pediatrics, Neurology and Neurosurgery, Montreal Children’s Hospital, McGill University Health Center Montreal, Quebec, Canada
                [11 ]Department of Pediatric Neurology, Erasmus University Hospital – Sophia Children’s Hospital Rotterdam, The Netherlands
                [12 ]Division of Biochemical Diseases, Department of Pediatrics, BC Children’s Hospital, Centre for Molecular Medicine and Therapeutics, University of British Columbia Vancouver, Canada
                [13 ]Centre for Rare diseases, Department of Paediatrics, Aarhus University Hospital Aarhus, Denmark
                [14 ]Department of Child Neurology, Kaiser Permanente Pediatric Specialties Roseville, California
                [15 ]Department of Pediatric Neurology, Hamad Medical Corp Doha, Qatar
                [16 ]Department of Child Neurology, Radboud University Medical Center Nijmegen, The Netherlands
                [17 ]Department of Medical Genetics, University of British Colombia Vancouver, Canada
                [18 ]Child Neurology and Psychiatry Unit, C. Mondino National Neurological Institute Pavia, Italy
                [19 ]Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, VU University Amsterdam, The Netherlands
                [20 ]Department of Biological Sciences, University of Delaware Newark, Delaware
                [21 ]Department of Pediatrics, Jefferson Medical College, Thomas Jefferson University Philadelphia, Pennsylvania
                Author notes
                Correspondence Nicole I. Wolf, Department of Child Neurology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. Tel: +31-20-44 40859; Fax: +31-20-44 440844; E-mail: n.wolf@ 123456vumc.nl
                [a]

                These authors share first authorship.

                [b]

                These authors share senior authorship.

                Funding Information The study received financial support from ZonMw TOP grant 91211005 (to S. H. K. and M. S. v. d. K.), the Optimix Foundation for Scientific Research (to M. S. v. d. K.), the ELA Foundation (ELA Grant 2009-045C3 and ELA Grant 2012-044PS5 to E. B.), the European Research Council (ERC Starting Grant 260888 to E. M. V.), the Fonds de Recherche du Québec en Santé (Research Scholar Junior 1 of FRQS) (to G. B.), the Fondation du Grand Defi Pierre Lavoie (grants to G. B.), the Canadian Institutes of Health Research (#301221 grant to C. D. M. v. K.), the Michael Smith Foundation for Health Research Scholar award (to C. D. M. v. K.), the National Institutes of Health (P20GM103464 and R01NS058978 to G. M. H.), the Kylan Hunter Foundation and the PMD Foundation (to G. M. H.).

                Article
                10.1002/acn3.203
                4479525
                26125040
                6109d3ff-8ce4-4586-9ecc-840b107813e0
                © 2015 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.

                This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

                History
                : 14 January 2015
                : 03 March 2015
                : 12 March 2015
                Categories
                Research Articles

                Comments

                Comment on this article